CDER Drug Safety Oversight Board To Receive Unprecedented External Input, Galson Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The Center for Drug Evaluation & Research's Drug Safety Oversight Board will include an unprecedented level of external input, CDER Acting Director Steven Galson said
You may also be interested in...
IoM Drug Safety Committee Meeting
The Institute of Medicine committee charged with reviewing the drug safety system will hold its second meeting July 19-20
IoM Drug Safety Committee Meeting
The Institute of Medicine committee charged with reviewing the drug safety system will hold its second meeting July 19-20
Drug Safety Board Is Biased By Connection To CDER, Sen. Grassley Says
Grassley is asking FDA to outline the specific steps that will be taken to ensure the independence of the committee. A letter to FDA Acting Commissioner Crawford was released the same day the Institute of Medicine convened its meeting to study FDA’s drug safety review practices.